Vaccination therapy in prostate cancer
| Autor: | Roberto Salvioni, Giorgio Parmiani, Sergio Villa, Manuela Iero, Riccardo Valdagni, Lorenzo Pilla, Licia Rivoltini, Andrea Marrari |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Immunology Cancer Vaccines Androgen deprivation therapy Prostate cancer Antigen Internal medicine medicine Humans Immunology and Allergy Clinical Trials as Topic business.industry Prostatectomy Prostatic Neoplasms medicine.disease Combined Modality Therapy Clinical trial Radiation therapy Vaccination Cancer vaccine business |
| Zdroj: | Cancer Immunology, Immunotherapy. 56:429-445 |
| ISSN: | 1432-0851 0340-7004 |
| DOI: | 10.1007/s00262-006-0233-8 |
| Popis: | Radical prostatectomy and radiation therapy provide excellent localized prostate cancer (PC) control. Although the majority of prostate carcinoma is nowadays diagnosed at early stages with favourable risk features, in patients up to 30-40% it recurs within 10 years. Furthermore, the lack of effective therapies, once prostate carcinoma becomes refractory to androgen deprivation, mandates the development of alternative therapeutic options. There is a growing interest in harnessing the potency and specificity of anti-tumour immunity through the generation of fully competent dendritic cells and tumour reactive effector lymphocytes. Several strategies to treat or prevent the development of metastatic PC have been explored in clinical trials and are summarized in this review, considering also the feasibility and safety of these approaches. In some cases clinical responses were achieved showing that vaccine-primed T cells induced anti-tumour activity in vivo. The present findings and perspectives of the immunologic interventions in PC patients will be discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink